{"schema_version":"secwatch.filing_event.v1","accession":"0001001233-26-000002","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2026-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.366810+00:00","generated_at":"2026-05-16T05:12:47.725510+00:00","sec_items":["2.02","5.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Sangamo reports ~$20.9M preliminary cash; CFO terminates, interim CFO appointed","bullets":["Preliminary cash and cash equivalents as of Dec 31, 2025: ~$20.9 million (unaudited, subject to change).","CFO Prathyusha Duraibabu's employment terminated effective Feb 2, 2026.","Nikunj Jain (VP Finance, Controller) appointed Interim CFO effective Feb 3, 2026; no additional compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001001233-26-000002","json":"https://secwatch.observer/filing/0001001233-26-000002.json","markdown":"https://secwatch.observer/filing/0001001233-26-000002.md","text":"https://secwatch.observer/filing/0001001233-26-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000100123326000002/0001001233-26-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000100123326000002/sgmo-20260202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:12:47.725510+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}